Based on these results, despite the fact that the data of OS are immature, this combination has been approved by the FDA (US Food and Drug Administration) for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.